Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies
Articles
SPECIAL FEATURE – Formulation Development & Manufacturing – CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
SPECIAL FEATURE – Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
NANOTECHNOLOGY MARKET – Nanotechnology Markets in Healthcare & Medicine November 19, 2014
Kevin James, Jackson Highsmith, and Paul Evers report the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate of 22%. The biggest increase will come in the area of drug delivery systems.
SPECIAL FEATURE – Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
ANTIBODY DRUG CONJUGATES – ADC Development Using SMARTag(TM) Technology April 1, 2014
Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part II of III October 15, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs December 31, 2012
Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.
12/5/2012 November 29, 2012
Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group,...8/29/2012 August 26, 2012
Synergy Pharmaceuticals Acquires BMS Drug Synergy Pharmaceuticals Inc. recently announced it has signed an Asset Purchase Agreement with Bristol-Myers Squibb...5/23/2012 May 20, 2012
Agilent to Acquire Cancer Diagnostic Company for $2.2 Billion Agilent Technologies Inc. and EQT, the Sweden-based private equity group, recently...3/13/2012 March 7, 2012
Aegerion Pharmaceuticals Submits US & EU Marketing Applications Aegerion Pharmaceuticals, Inc. recently announced it has submitted an NDA to the...
